SYRA VS ABBV Stock Comparison
Performance
SYRA10/100
10/100
SYRA returned -63.43% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
ABBV100/100
100/100
ABBV returned -4.80% in the last 12 months. Based on SPY's performance of -20.59%, its performance is above average giving it a score of 100 of 100.
Volatility
SYRA33/100
33/100
SYRA has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.
ABBV47/100
47/100
ABBV has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
Analyst Price Targets
SYRA
"Analyst Price Targets" not found for SYRA
ABBV68/100
68/100
20 analysts offer 12-month price targets for ABBV. Together, they have an average target of 158.73, the most optimistic target put ABBV at 200 within 12-months and the most pessimistic has ABBV at 127.
Sentiment
SYRA
"Sentiment" not found for SYRA
ABBV71/100
71/100
ABBV had a bullish sentiment score of 71.15% across Twitter and StockTwits over the last 12 months. It had an average of 130.21 posts, 1,504.50 comments, and 7,664.76 likes per day.
Technicals
SYRA
"Technicals" not found for SYRA
ABBV11/100
11/100
ABBV receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
SYRA
"Earnings" not found for SYRA
ABBV100/100
100/100
ABBV has missed earnings 0 times in the last 20 quarters.
Profit
SYRA
"Profit" not found for SYRA
ABBV80/100
80/100
Out of the last 20 quarters, ABBV has had 18 profitable quarters and has increased their profits year over year on 11 of them.
Dividend
SYRA
"Dividend" not found for SYRA
ABBV100/100
100/100
ABBV's most recent dividend was $0.97 per share, based on a share price of $138.93. It was a payout ratio of 53.19% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
Syra Health Corp. Class A Common Stock Summary
Nasdaq / SYRA
Healthcare
Medical - Care Facilities
Syra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, including medical communications, patient education, and healthcare training; and population health management services, such as analytics as a service, epidemiology, and health equity analytics solutions. The company also engages in developing Syrenity, an on-demand telehealth platform for mental health services. In addition, the company provides healthcare staffing solutions; and digital health solutions comprising digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana.
ABBVIE INC. Summary
New York Stock Exchange / ABBV
Healthcare
Drug Manufacturers - General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare SYRA to other companies in the same or a similar industry.